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Metaplasia, wherein 1 type of adult tissue replaces another, is a consequence of chronic 
inflammation.1 Presumably, metaplasias develop and persist because they are more adept 
than the native tissue at resisting injury from the underlying inflammatory condition. In the 
stomach, intestinal metaplasia develops in the setting of chronic Helicobacter pylori gastritis, 
whereas intestinal metaplasia in the esophagus results from chronic esophagitis caused by 
gastroesophageal reflux disease (GERD). Limited dialogue between investigators studying 
intestinal metaplasia in the stomach and those studying it in the esophagus has been a barrier 
to progress in understanding these conditions. The 2016 James W. Freston Conference of the 
American Gastroenterological Association was unique in bringing these groups together. 
Senior investigators delivered lectures on basic and clinical features of intestinal metaplasia 
in the esophagus and stomach, and young faculty and trainees gave oral and poster 
presentations.
Introductory Session
Robert Genta reviewed the histologic features of intestinal metaplasia, and Jason Mills 
provided a historical overview, noting that Rudolph Virchow coined the term “metaplasia” at 
the VIIIth International Medical Congress in Copenhagen in 1884. In 1900, the pathologist 
George Adami presciently contended that there are “mother” (stem) cells that regenerate 
normal tissue and, “under abnormal conditions, the fully differentiated functioning cells of 
certain tissues are capable of proliferation and giving rise to cells of like nature, but this is 
only after a preliminary reversion to a simpler, more embryonic type.” Adami proposed that 
this process of dedifferentiation leading to increased proliferation might result in “glandular 
cancer.”2 During the 1930s, developmental biologists largely abandoned Adami’s concepts, 
instead embracing Conrad Waddington’s notion that stem cell differentiation was 
unidirectional. However, recent evidence vindicates Adami, showing that differentiated cells 
can indeed contribute to metaplasia.
Clinical and Histologic Issues Session
Stuart Spechler reviewed how concepts about intestinal metaplasia have evolved. Early 
investigators thought intestinal epithelium in the stomach was congenital, and not until the 
1930s did it become widely regarded as a metaplasia caused by gastritis.3 In the 1970s, 
Japanese pathologists categorized intestinal metaplasia associated with gastric cancer as 
“complete” or “incomplete” based on how closely it resembled normal small intestine.4 In 
the 1980s, Jass and Filipe5 used mucin immunohistochemistry to categorize 2 types of 
intestinal metaplasia in the stomach. Type I was histologically “complete,” comprising 
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absorptive cells and goblet cells expressing sialomucins. Type II was “incomplete,” 
comprising goblet cells and gastric foveolar-like cells, and subcategorized as IIB if it 
expressed colonic-type sulfomucins, and as IIA if it did not. Esophageal researchers instead 
used terms like “specialized columnar epithelium” and “specialized intestinal metaplasia” to 
categorize the incomplete intestinal metaplasia of Barrett’s esophagus. By the 1980s, it had 
become accepted that chronic reflux esophagitis resulted in intestinal metaplasia that 
predisposed to esophageal adenocarcinoma.6 In the 1990s, Pelayo Correa proposed that 
chronic H pylori gastritis caused the intestinal metaplasia that predisposed to gastric 
adenocarcinoma.7
Ernst Kuipers reviewed data on cancer risk for intestinal metaplasia. Recent, population-
based studies describe esophageal adenocarcinoma incidence rates for Barrett’s esophagus 
in the range of 1.2 to 1.6 per 1,000 patient-years.8–10 Dr Kuipers debunked the popular 
notion that intestinal metaplasia in the stomach has a lower cancer risk than in Barrett’s 
esophagus, noting a study of 97,837 Dutch patients with preneoplastic gastric lesions that 
found a gastric cancer incidence of 4 per 1000 patient-years,11 with similar incidence rates 
found in cohorts from the United States and Sweden.12,13 As in the esophagus, cancer risk in 
the stomach is proportional to the extent of intestinal metaplasia. Therefore, physicians 
should consider endoscopic surveillance for patients with extensive gastric intestinal 
metaplasia (involving both the antrum and the fundus).14,15 Surveillance can lead to early 
detection of gastric cancer and improved survival, but data showing that endoscopists miss 1 
out of 9 early cancers suggest that recognition of these early lesions needs improvement.16
Robert Odze explained that Barrett’s metaplasia has (1) a surface/crypt epithelial 
compartment with columnar cells exhibiting variable degrees of gastric and intestinal 
differentiation, and (2) an underlying glandular compartment composed of mucus glands, 
oxyntic glands, or both. Although goblet cells have been considered the sine qua non for 
Barrett’s intestinal metaplasia, Dr Odze noted that esophageal nongoblet columnar 
epithelium also expresses transcription factors of intestinal differentiation.17 Furthermore, 
goblet cells can be missed by biopsy sampling error,18 and nongoblet esophageal cells can 
be mistaken for goblet cells, resulting in false-negative and false-positive Barrett’s 
diagnoses, respectively.19 Nongoblet esophageal columnar epithelium can exhibit DNA 
content abnormalities,20 and a recent report found an inverse association between goblet cell 
density in Barrett’s metaplasia and risk of esophageal adenocarcinoma.21 Dr Odze noted that 
it is inaccurate to call esophageal nongoblet columnar epithelium “cardiac epithelium,” 
because it is the underlying mucus gland compartment that identifies mucosa as cardiac type 
(not the surface/crypt epithelium). He concluded that goblet cells are not a consistent, 
sensitive, or specific biomarker for Barrett’s esophagus or its cancer risk.
Nicholas Shaheen explained why it is difficult to estimate the cancer risk for cardiac mucosa 
without goblet cells. Despite the high prevalence of this mucosal type in the general 
population,22,23 studies on its cancer risk have focused largely on patients with GERD 
symptoms who have cardiac mucosa extending above the gastric folds into the esophagus. It 
is unclear if their cancer risk differs from asymptomatic individuals with cardiac epithelium 
at a normally positioned Z-line. Furthermore, some studies have found a cancer risk similar 
to that for Barrett’s patients, whereas others have shown a much lower cancer risk.24–27 The 
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reasons for these discrepancies are unclear, but may include inadequate biopsy sampling 
(misclassifying patients as intestinal metaplasia-negative),28,29 small study sample sizes, and 
short durations of follow-up. Dr Shaheen concluded that, presently, no blanket 
recommendation for surveillance of patients with cardiac mucosa is advisable.
Parakrama Chandrasoma presented his controversial contention that cardiac mucosa without 
goblet cells is never normal and always metaplastic, irrespective of whether it is found above 
or below the endoscopically identified gastroesophageal junction. He cited a study showing 
that cardiac mucosa exhibits the same morphologic and molecular features irrespective of its 
location,30 and discussed reasons to believe that cardiac mucosa represents a squamous-
tocolumnar metaplasia of the esophagus caused by GERD.31 Endoscopists demarcate the 
gastroesophageal junction at the top of gastric folds, but Dr Chandrasoma argued that this is 
an unreliable landmark in GERD patients in whom the distal esophagus has dilated and 
developed rugal-like folds easily mistaken for gastric folds.32,33 Dr Chandrasoma proposed 
that the finding of cardiac mucosa might be used as an objective, histologic marker for the 
presence of GERD.
Stem Cells and their Lineage in Normal Development Session
Anil Rustgi explained that the esophagus has a prototypical stratified squamous epithelium 
with proliferative basal cells abutting the basement membrane. These basal cells undergo 
lineage allocation as they migrate toward the epithelial surface, becoming early 
differentiated suprabasal cells and terminally differentiated superficial squamous cells that 
ultimately desquamate. Experiments performed by Dr Veronique Giroux have identified a 
murine esophageal progenitor cell population.34 Using genetic in vivo lineage tracing, she 
found that the keratin 15 (Krt15) promoter marked a long-lived basal cell population capable 
of allocating all stages of differentiation, and that genetic depletion of Krt15 lineage-labeled 
cells resulted in decreased proliferation and epithelial atrophy. Radioresistant Krt15+ cells 
fostered regeneration following radiation-induced esophageal injury, and Krt15+ cells in 3-
dimensional organoids exhibited enhanced clonogenicity. Dr Rustgi concluded that this 
Krt15+ long-lived progenitor cell population might constitute an esophageal stem cell 
population.
Expanding on his earlier discussion that metaplasias can develop when mature cells 
dedifferentiate and proliferate, Jason Mills discussed the contribution of factors like the 
basic helix–loop–helix transcription factor MIST1 to this process.35 Increased expression of 
these factors can scale up a cell’s energy use toward maintaining an elaborate secretory 
apparatus (differentiated status), whereas decreased expression can scale down these 
processes as the cell undergoes dedifferentiation and reversion to a proliferative state. Dr 
Mills also discussed evidence that quiescent, differentiated cells are recruited back into the 
cell cycle during metaplasia via an evolutionarily conserved, invariant sequence of steps. 
Each step can be blocked by pharmacologic inhibitors or by genetic modifications in mice.
Yoku Hayakawa discussed his observation that Mist1 messenger RNA is expressed, not only 
in gastric chief cells, but also in quiescent stem cells in the isthmus of gastric corpus glands.
36
 Chief cell ablation experiments suggest that it is Mist1+ isthmus stem cells (not Mist1+ 
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chief cells) that are responsible for long-term lineage tracing in the gastric corpus. With the 
induction of mutant Kras, Mist1+ isthmus stem cells serve as the cell of origin for intestinal 
metaplasia, and give rise to both intestinal-type and diffuse-type gastric cancers when they 
lose Apc and E-cadherin, respectively. Dr Hayakawa concluded that Mist1+ stem cells in the 
isthmus of gastric glands likely are the main source of metaplasia and cancers in the 
stomach.
Kay Lund described a Sox9-EGFP reporter mouse model that identifies intestinal epithelial 
cell subtypes by their levels of Sox9-EGFP expression. These include (1) “actively cycling” 
intestinal epithelial stem cells (IESC; Sox9-EGFPLow), (2) IESC progenitors (Sox9-
EGFPSublow), (3) enteroendocrine cells (Sox9-EGFPHigh), and (4) differentiated enterocytes, 
Paneth cells, and goblet cells (Sox9-EGFPNegative). After intestinal injury, a reserve 
population of Sox9-EGFPHigh cells is activated to fuel expansion of Sox9-EGFPLow IESC 
during regeneration.37 IESC exhibit enrichment of insulin-like growth factor 1 receptor 
(IGF1R) and insulin receptor isoform-A, and sustained insulin receptor signaling seems to 
protect against adenomas, perhaps by inhibiting IGF1R signaling.38,39 MicroRNA 
(miR375), which has been linked both to cancer and IGF1R regulation, is enriched in IESC 
and can limit their proliferation.40 Dr Lund concluded that maintained expression and 
function of insulin receptors might regulate IESC and prevent adenomas, potentially by 
inhibiting IGF1R, and that miR375 could be a new target to limit IESC proliferation and 
tumor growth.
Peter Storz discussed how studies on pancreatic acinar-to-ductal metaplasia (ADM) might be 
applied to intestinal metaplasia in the esophagus and stomach. In the pancreas, inflammatory 
macrophages produce factors such as tumor necrosis factor, IL-6, and RANTES that 
contribute to ADM development.41,42 This ADM becomes irreversible when it acquires an 
oncogenic KRas mutation, and neoplastic progression occurs in synergy with inflammation.
43
 Nonneoplastic ADM is associated predominantly with inflammatory macrophages, but 
alternatively activated macrophages, which can drive fibrosis and lesion growth, become 
more plentiful as neoplasia develops.44 Interleukins released by cells in precancerous ADM 
lesions initiate this phenotypic switch in macrophage populations. Thus, using the pancreas 
as an example, Dr Storz implicated inflammation and inflammatory macrophages as 
initiators and drivers of the metaplasia–neoplasia sequence.
Potential Origins of Metaplasia in the Esophagus and Stomach Session
David Wang reviewed unique anatomic features of the mice and rats used in metaplasia 
studies, noting that these rodents have a forestomach lined by squamous epithelium and an 
esophagus that lacks submucosal glands. The rodent esophagus joins stomach at the junction 
between squamous-lined forestomach and distal glandular stomach, and the 
squamocolumnar junction has a distinctive “first fundic gland” containing cells that express 
stem cell markers including LGR5 and DCLK-1.45,46
Jianwen Que reviewed mechanisms controlling normal gastroesophageal embryonic 
development. Around embryonic days 9.5-11.0, live imaging reveals a saddle-like structure 
that separates esophagus and stomach from trachea and lung.47 Genetic models suggest that 
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transcription factors (eg, SOX2, NKX2.1) and signaling molecules (eg, Noggin, Wnt2/2b) 
are critical for establishing esophagus from foregut,48 after which esophageal lining changes 
from columnar into squamous epithelium under control of transcription factors like p63 and 
SOX2. A p63 gene deletion prevents this epithelial change, and SOX2 down-regulation 
causes esophageal progenitor cells to differentiate abnormally into mucin-secreting cells.
48,49
 Bmp signaling in the esophagus also is required for normal development of squamous 
epithelium.50 In the stomach, multiple signaling pathways (eg, Bmp, Notch, Wnt) and 
transcription factors (eg, BARX1, NKX2.5, and GATA3) mediate the development of gastric 
glandular epithelia.
Ramesh Shivdasani discussed how cellular identity is influenced by thousands of distant 
enhancers that regulate gene transcription, dictated by chromatin structure.51,52 His 
laboratory has mapped the enhancer landscape in Barrett’s esophagus and in normal 
esophageal, gastric, and intestinal mucosae, elucidating how Barrett’s metaplasia reflects an 
intestinal enhancer signature and lacks vestiges of an esophageal enhancer signature. In 
studies on tissue-specific enhancers delineated during mouse organogenesis, the Shivdasani 
laboratory has found that, although thousands of enhancers specific to adult esophageal and 
intestinal epithelia are fully demarcated by birth, those regions of chromatin appear equally 
poised for activation in both mucosal primordia early in development. Dr Shivdasani 
anticipates that these studies will help to elucidate the chromatin basis of intestinal 
metaplasia in esophagus and stomach.
David Wang explained how transcommitment, the molecular reprogramming of a progenitor 
cell, is a possible mechanism whereby cells native to the esophagus could give rise to 
Barrett’s metaplasia. Transcommitment of squamous epithelial progenitor cells into 
intestinal-type columnar cells likely requires a stepwise process that includes the down-
regulation of squamous transcription factors, and sequential upregulation of columnar, 
intestinal, and mucus-associated transcription factors. Dr Wang also described potential roles 
for Hedgehog and downstream bone morphogenetic protein (BMP)-4 signaling pathways in 
regulating these transcription factors.53,54
Andrea Todisco explained that BMP signaling, which targets gastric epithelial cells in mice 
with Helicobacter gastritis, has important antiinflammatory actions and effects on 
gastrointestinal cell growth and differentiation.55,56 Mice genetically engineered to express 
noggin (a BMP inhibitor) in the stomach exhibit decreased parietal cell numbers, increased 
epithelial cell proliferation, and development of spasmolytic polypeptide-expressing 
metaplasia (SPEM).55,56 Noggin-expressing mice also show enhanced Helicobacter-induced 
inflammation and epithelial cell proliferation, accelerated dysplasia development, and 
increased expression of STAT3 and AID (molecules implicated in gastric tumorigenesis).56 
In isolated canine gastric epithelial cells, BMP4, BMP2, and BMP7 inhibit expression of 
IL8, a proinflammatory chemokine.56 Dr Todisco concluded that BMP signaling reduces 
inflammation, and decreases metaplasia and dysplasia development in the Helicobacter-
infected mouse stomach.
James Goldenring noted that both acute and chronic parietal cell depletion in mice leads to 
SPEM development in the gastric body.57 Lineage mapping shows that this SPEM emerges 
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through transdifferentiation of chief cells into metaplastic mucous cells.58 Although this 
process might promote wound repair,59 it can lead to intestinal metaplasia development in 
the setting of chronic inflammation. When chief cells are induced to express active KRas, 
SPEM develops throughout the gastric body within 2-3 weeks, and intestinal metaplasia 
appears by 3–4 months.60 Administration of a MEK inhibitor (Selumetinib) to mice 3 
months after active KRas induction leads to arrest of metaplasia and extrusion of metaplastic 
glands through recrudescence of normal gastric lineages from a dormant normal progenitor 
cell population.60 Dr Goldenring concluded that MEK inhibitors someday might be used to 
reverse metaplasia and enable repopulation of the gastric mucosa with normal oxyntic 
mucosal lineages.
Timothy Wang discussed mouse models suggesting a gastric cardia origin for Barrett’s 
metaplasia. L2–IL-1β mice, which overexpress IL-1β in the esophagus, develop a Barrett’s- 
like metaplasia that begins in the gastric cardia and expands into the esophagus.61 The 
gastric cardia normally is rich in stem/progenitor cells, including Lgr5+ and CCK2R+ cells, 
and transgenes marking either of those progenitor cell types can lineage-trace metaplasia in 
the L2–IL-1β mouse. Human Barrett’s esophagus and gastric cardia exhibit strong 
expression of CCK2R (a gastrin receptor), and progression of Barrett’s-like metaplasia in 
mice is accelerated by hypergastrinemia and inhibited by CCK2R blockade.62,63 Gamma-
secretase inhibitors, which block Notch signaling, increase goblet cells and reduce 
proliferation in rodent Barrett’s metaplasia, suggesting that Notch signaling might drive 
neoplastic progression.61,62 Dr Wang concluded that the abundance and activity of 
undifferentiated stem cells, rather than the presence of goblet cells, likely drives cancer risk 
in Barrett’s esophagus.64
Nicholas Wright explained that Barrett’s metaplasia exhibits a range of gland phenotypes, 
each showing functional compartmentalization, bidirectional migration, and derivation from 
a shared clonal progenitor.65 Barrett’s glands have an evolutionary life history, comprising 
segments exhibiting a spatial gradient of phenotypes as well as heterogeneous and 
differential tissue age, with older glands located proximally.66 Dr Wright suggested that the 
mechanism of phenotypic evolution in intestinal metaplasia is probably biased drift 
occurring after a multilineage stem cell change, followed by clonal expansion through gland 
fission.67 Because Barrett’s glands are clonal, they are units of selection, including selection 
in neoplastic progression.67 Although classically neoplasia develops only in goblet cell-
containing Barrett’s epithelium, Dr Wright noted that esophageal nongoblet columnar 
epithelium can also undergo clonal expansion and harbor premalignant TP53 mutations.68
Frank McKeon suggested that the identification of the Barrett’s cell of origin might inform 
preemptive therapies for eliminating Barrett’s esophagus. He and Wa Xian have traced the 
origin of Barrett’s-like metaplasia in mice to gastroesophageal junction cells with a unique 
developmental lineage.69 Using novel technologies for cloning gastrointestinal stem cells,70 
they cloned 3 distinct stem cells in the distal esophagus (ones committed to esophageal, 
gastric, and Barrett’s differentiation), and the Barrett’s stem cells exhibited genomic 
alterations typical of Barrett’s metaplasia.71 By extending these cloning techniques to 
patient-matched tissues, they have adapted Barrett’s and patient-matched gastric cardia stem 
cells to high-throughput drug screening platforms that have revealed molecules with 
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potentially selective toxicity for Barrett’s stem cells. This raises the intriguing possibility 
that such selectively toxic molecules might be used to eradicate Barrett’s metaplasia.
Inflammation and the Development of Metaplasia Session
Rick Peek highlighted the pivotal role of CagA, an H pylori oncoprotein, in intestinal 
metaplasia development in the stomach. CagA+ H pylori strains interact specifically with 
stem cells in gastric glands,72 and CagA can confer stemness properties to gastric epithelial 
cells.73 Dr Peek discussed the usefulness of H pylori eradication for inducing regression of 
intestinal metaplasia and, thereby, reducing gastric cancer risk. Novel therapies showing 
promise for inducing such regression in animal models were discussed, including MEK 
inhibitors used by the Goldenring laboratory.60 Finally, Dr Peek discussed the role of 
microbial species other than H pylori in generating gastric intestinal metaplasia, and he 
identified potential collaborations between H pylori and other constituents of the gastric 
microbiota as promising areas for future research.74
Rhonda Souza discussed her studies on reflux esophagitis pathogenesis. In a rat model, she 
found that refluxed acid and bile did not kill esophageal squamous cells directly, but rather 
stimulated them to release inflammatory cytokines.75 To test her concept that reflux 
esophagitis develops as a cytokine-mediated injury, she studied acute reflux esophagitis 
induced by stopping proton pump inhibitors in patients with reflux esophagitis healed by 
proton pump inhibitors.76 Reflux esophagitis returned within 2 weeks, and this human acute 
reflux esophagitis was characterized histologically by T lymphocyte infiltration of 
esophageal mucosa. In vitro studies showed that acid and bile salts cause esophageal 
epithelial cells to stabilize hypoxia inducible factor (HIF)-2α, a transcription factor that can 
increase proinflammatory molecule expression.77 In patients developing reflux esophagitis, 
she found a positive correlation between increased esophageal HIF-2α levels and increased 
proinflammatory molecule expression. These studies suggest that gastroesophageal reflux 
causes esophagitis through cytokine-mediated mechanisms triggered by HIF-2α.
Juanita Merchant discussed her studies showing that acute Helicobacter felis in mice causes 
gastric parietal cells to release sonic hedgehog that recruits myeloid cells into the stomach.78 
Chronic Helicobacter gastritis induces parietal cells to atrophy and release damage-
associated factors that polarize the myeloid cells in the stomach toward an 
immunosuppressive phenotype. The resulting myeloid-derived suppressor cells (MDSCs) 
create an environment favoring metaplasia. Myeloid cell polarization into MDSCs requires 
hedgehog-regulated transcription factor GLI1, which induces gastric MDSCs to express 
Schlafen 4, a myeloid differentiation factor.79 Dr Merchant showed that a nucleic acid 
signature for MDSCs in plasma correlates with gastric metaplasia presence in both mice and 
humans. Collectively, her studies suggest that MDSCs are present in the gastric 
microenvironment before neoplastic transformation, and that they might serve as a 
biomarker for gastric cancer risk.
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Models of Metaplasia in the Esophagus and Stomach Session
Robert Odze discussed his study on intestinal metaplasia development in rats with reflux 
esophagitis induced by esophagojejunostomy.80 Esophageal ulceration developed at the 
esophagojejunal anastomosis at postoperative week 2 and, over subsequent weeks, 
esophageal columnar epithelium with intestinal-type immunohistochemical features seemed 
to arise from budding jejunal crypts migrating into the ulcerated distal esophagus. Dr Odze 
concluded that these findings support a wound healing model for Barrett’s metaplasia 
pathogenesis in which gastric columnar cells migrate proximally to repair the reflux-
damaged distal esophagus.
Thai Pham noted that an ideal animal model for Barrett’s esophagus would be inexpensive 
and technically simple, using gastroesophageal reflux to induce metaplasia in genetically 
modifiable animals with a human-like esophagus. Most Barrett’s models have involved the 
surgical induction of reflux through esophagoenterostomy in rats. Although this model is 
inexpensive and technically simple, rats are not easily manipulated genetically, and the rat 
esophagus differs substantially from human. Dr Pham discussed his model of Barrett’s 
esophagus in mice,81 noting that the surgery is technically challenging, but the ability to 
genetically manipulate mice is a major advantage. He concluded that rodent models of 
Barrett’s esophagus are useful, albeit not ideal, investigational tools.
James Fox explained how early attempts to develop animal models of chronic H pylori 
gastritis were unsuccessful until investigators used H felis (a close relative of H pylori) to 
infect germfree Swiss Webster mice.82 In C57BL and INS/ GAS mice, H felis (and later 
mouse- adapted H pylori) recapitulated human H pylori lesions including parietal and chief 
cell depletion and SPEM development.83–86 Although SPEM lacks goblet cells, the 
predominant SPEM phenotype that develops in mice infected with H felis or H pylori87 and 
in gerbils infected with H pylori88 has intestinal features. Non- Helicobacter gut bacteria can 
profoundly influence the degree and severity of Helicobacter gastritis, especially when the 
Helicobacter infection causes parietal cell loss with achlorhydria that enables other 
organisms to colonize the stomach.89,90 Dr Fox noted that both the gender of C57BL mice 
and their commercial source influence the degree of gastritis and metaplasia developing with 
H pylori infection,91 and that the origin of the metaplastic lineages remains unclear.
Conclusions
The 2016 Freston Conference was unique in bringing experts on intestinal metaplasia in the 
esophagus together with experts on intestinal metaplasia in the stomach. The conference 
provided opportunities for new collaborations among established investigators, and a 
stimulating environment for young investigators and trainees to interact with senior 
scientists. The conference highlighted numerous similarities between gastric and esophageal 
intestinal metaplasia, suggesting that the mechanisms underlying metaplasia in these 
adjacent organs are not as dissimilar as has been assumed. For future studies, it might be 
more productive to focus on those similarities rather than differences.
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